Short answer
Eledon Pharmaceuticals, Inc. (ELDN) filed an 8-K current report with the SEC on June 22, 2026 reporting Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item 5.07 (Submission of Matters to a Vote of Security Holders). Stockholders approved a charter amendment at the June 18, 2026 Annual Meeting.
Eledon Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.03 · Amendments to Articles of Incorporation or Bylaws
- Stockholders approved a charter amendment at the June 18, 2026 Annual Meeting
- Amendment details are incomplete in the provided filing excerpt, limiting assessment of shareholder-rights impact
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Three Class III directors elected through 2029, preserving board continuity
- Authorized common shares increased 50%, from 300 million to 450 million
- Expanded share authorization increases financing flexibility but potential dilution capacity
- Deloitte & Touche LLP ratified as independent auditor for 2026 with 56,010,539 votes for
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Eledon Pharmaceuticals, Inc. 8-K filings
Get the next ELDN 8-K as it lands
Follow ELDN for push alerts, or ask the research agent what this filing means.